Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Bioatla Inc

Current price
2.63 USD -0.23 USD (-7.89%)
Last closed 2.86 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 147 175 904 USD
Yield for 12 month -31.28 %
21.11.2021 - 28.11.2021

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California. Address: 11085 Torreyana Road, San Diego, CA, United States, 92121

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
MSFT MSFT Microsoft


WallStreet Target Price

11.5 USD

P/E ratio

Dividend Yield

Current Year

Last Year

Current Quarter

Last Quarter

Current Year

-1 221 000 USD

Last Year

-1 199 000 USD

Current Quarter

-368 000 USD

Last Quarter

-270 000 USD

Key Figures BCAB

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -128 466 000 USD
Operating Margin TTM
PE Ratio
Return On Assets TTM -46.93 %
PEG Ratio
Return On Equity TTM -98.37 %
Wall Street Target Price 11.5 USD
Revenue TTM
Book Value 1.47 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 31.6 %
Dividend Yield
Gross Profit TTM -79 347 000 USD
Earnings Share -2.58 USD
Diluted Eps TTM -2.58 USD
Most Recent Quarter IV 2023
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics BCAB

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History BCAB

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation BCAB

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 134.3737
Price Sales TTM 989.2236
Enterprise Value EBITDA -0.3233
Price Book MRQ 2.1302

Financials BCAB

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators BCAB

For 52 weeks

1.24 USD 4.07 USD
50 Day MA 2.8 USD
Shares Short Prior Month 5 127 011
200 Day MA 2.33 USD
Short Ratio 11.56
Shares Short 5 588 159
Short Percent 12.64 %

Dynamics of changes in the value of assets




414.58 USD Microsoft Corporation +0.12 (+0.03%)
Detailed analytics

ETF funds



208.70 CHF iShares MDAX UCITS ETF (DE) -11.84 (-4.92%)
Detailed analytics



2169.94 USD Gold -5.94 (-0.27%)
Detailed analytics